Sanofi, GSK to apply for COVID-19 vaccine candidate approval

PARIS, February 23 (Reuters) – French drugmaker Sanofi (SASY.PA) and its UK partner GlaxoSmithKline (GSK.L) said Wednesday that they intend to submit data from their booster and Phase III efficacy trials as a basis for regulatory applications for a COVID-19 vaccine.

“We are very pleased with this data, which confirms our strong science and the benefits of our COVID-19 vaccine. The Sanofi-GSK vaccine demonstrates a universal ability to boost all platforms and across all ages,” said Thomas Triomphe, executive vice. President of Sanofi Vaccines.

The two companies had surprised investors in late December by postponing data on their COVID-19 booster candidate to this year. Read more

In September 2021, Sanofi dropped plans for its own mRNA-based COVID-19 vaccine due to the dominance gained by BioNTech-Pfizer (22UAy.DE)
(PFE.N) and Modern (MRNA.O) in using the technology to combat the pandemic. L1N2QU0BI

Sanofi is hoping for a comeback after falling behind rivals in the race for COVID-19 vaccines, with this candidate based on the more conventional protein-based approach. Read more

Reporting by Sudip Kar-Gupta and Benoit Van Overstraeten; editing by Jason Neely

Our standards: Thomson Reuters trust principles.